DRTG(SH:600329)2025-04-29 09:40Financial Performance - The company's operating revenue for Q1 2025 was ¥1,455,299,952.25, a decrease of 30.22% compared to ¥2,085,588,390.55 in the same period last year[2] - Net profit attributable to shareholders was ¥374,247,760.07, down 3.38% from ¥387,326,165.82 year-on-year[2] - Total revenue for Q1 2025 was CNY 1,455,299,952.25, a decrease of 30.1% compared to CNY 2,085,588,390.55 in Q1 2024[16] - Net profit for Q1 2025 was CNY 371,785,463.35, a decrease of 3.0% from CNY 383,381,748.70 in Q1 2024[16] - Earnings per share for Q1 2025 was CNY 0.49, unchanged from CNY 0.50 in Q1 2024[17] Cash Flow - The net cash flow from operating activities increased significantly by 498.13%, reaching ¥355,525,720.74, compared to a negative cash flow of -¥89,299,402.45 in the previous year[2] - Operating cash flow for Q1 2025 was CNY 355,525,720.74, compared to a negative cash flow of CNY -89,299,402.45 in Q1 2024[20] - Cash inflow from operating activities was CNY 1,218,073,248.73, down from CNY 1,737,890,346.16 in Q1 2024[20] - The company experienced a net decrease in cash and cash equivalents of -$1.49 billion during the period[21] - Cash and cash equivalents decreased from ¥2,944,432,686.21 to ¥1,454,568,332.22[11] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,167,867,980.27, reflecting a 3.71% increase from ¥10,768,625,044.29 at the end of the previous year[3] - The total assets as of March 31, 2025, are ¥11,167,867,980.27, compared to ¥10,768,625,044.29 at the end of 2024[12] - The total liabilities increased from ¥4,160,561,516.07 to ¥5,471,481,096.13 over the same period[12] - Total liabilities as of the reporting date were CNY 2,946,260,395.43, an increase from CNY 2,918,688,717.32 year-over-year[16] - The company's total current assets as of March 31, 2025, amount to ¥5,696,386,884.14, a decrease from ¥6,608,063,528.22 as of December 31, 2024[11] Shareholder Information - The total number of common shareholders at the end of the reporting period is 52,324[8] - Tianjin Pharmaceutical Group Co., Ltd. is the largest shareholder, holding 331,120,528 shares, which accounts for 42.997% of the total shares[9] - ABN AMRO CLEARING BANK N.V. holds 72,763,900 shares, representing 9.449% of the total shares[9] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[9] Investment and Financing - The company's investment income decreased by 31.36% due to a reduction in the equity stake in a joint venture, resulting in lower returns[6] - The company's short-term borrowings increased by 234.51%, indicating a rise in reliance on short-term financing[5] - The company reported a short-term loan of ¥72,431,607.62, up from ¥21,653,247.51[12] - The net cash flow from investing activities was -$1.85 billion, with total cash outflows from investing activities amounting to $2.42 billion[21] - The company reported a cash inflow of $300 million from borrowing activities[21] Future Outlook - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[2] - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[21] - The company’s cash flow management strategies will be crucial in navigating the upcoming financial adjustments and market conditions[21]